PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome - PubMed (original) (raw)
. 2014 Mar 27;33(13):1621-8.
doi: 10.1038/onc.2013.119. Epub 2013 May 20.
Affiliations
- PMID: 23686313
- DOI: 10.1038/onc.2013.119
PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome
A V Antonov et al. Oncogene. 2014.
Abstract
Multiple clinical studies have correlated gene expression with survival outcome in cancer on a genome-wide scale. However, in many cases, no obvious correlation between expression of well-known tumour-related genes (that is, p53, p73 and p21) and survival rates of patients has been observed. This can be mainly explained by the complex molecular mechanisms involved in cancer, which mask the clinical relevance of a gene with multiple functions if only gene expression status is considered. As we demonstrate here, in many such cases, the expression of the gene interaction partners (gene 'interactome') correlates significantly with cancer survival and is indicative of the role of that gene in cancer. On the basis of this principle, we have implemented a free online datamining tool (http://www.bioprofiling.de/PPISURV). PPISURV automatically correlates expression of an input gene interactome with survival rates on >40 publicly available clinical expression data sets covering various tumours involving about 8000 patients in total. To derive the query gene interactome, PPISURV employs several public databases including protein-protein interactions, regulatory and signalling pathways and protein post-translational modifications.
Similar articles
- p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.
Yan W, Zhang J, Zhang Y, Jung YS, Chen X. Yan W, et al. Mol Cell Biol. 2012 Jul;32(13):2336-48. doi: 10.1128/MCB.00215-12. Epub 2012 Apr 16. Mol Cell Biol. 2012. PMID: 22508983 Free PMC article. - Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma.
Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Li C, et al. J Invest Dermatol. 2008 Jun;128(6):1585-8. doi: 10.1038/sj.jid.5701186. Epub 2007 Nov 29. J Invest Dermatol. 2008. PMID: 18049450 Free PMC article. No abstract available. - MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. Azmi AS, et al. Eur J Cancer. 2010 Apr;46(6):1122-31. doi: 10.1016/j.ejca.2010.01.015. Epub 2010 Feb 13. Eur J Cancer. 2010. PMID: 20156675 Free PMC article. - p53 Family isoforms.
Bourdon JC. Bourdon JC. Curr Pharm Biotechnol. 2007 Dec;8(6):332-6. doi: 10.2174/138920107783018444. Curr Pharm Biotechnol. 2007. PMID: 18289041 Free PMC article. Review. - p73: a chiaroscuro gene in cancer.
Marabese M, Vikhanskaya F, Broggini M. Marabese M, et al. Eur J Cancer. 2007 Jun;43(9):1361-72. doi: 10.1016/j.ejca.2007.01.042. Epub 2007 Apr 10. Eur J Cancer. 2007. PMID: 17428654 Review.
Cited by
- Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways.
Varisli L, Cen O, Vlahopoulos S. Varisli L, et al. Immunology. 2020 Mar;159(3):257-278. doi: 10.1111/imm.13160. Epub 2019 Dec 22. Immunology. 2020. PMID: 31782148 Free PMC article. Review. - Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment.
Wawrzyniak D, Grabowska M, Głodowicz P, Kuczyński K, Kuczyńska B, Fedoruk-Wyszomirska A, Rolle K. Wawrzyniak D, et al. PLoS One. 2020 Aug 20;15(8):e0237889. doi: 10.1371/journal.pone.0237889. eCollection 2020. PLoS One. 2020. PMID: 32817625 Free PMC article. - SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.
Chen X, Wang YW, Gao P. Chen X, et al. J Exp Clin Cancer Res. 2018 May 9;37(1):100. doi: 10.1186/s13046-018-0748-9. J Exp Clin Cancer Res. 2018. PMID: 29743122 Free PMC article. - The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
Golden E, Rashwan R, Woodward EA, Sgro A, Wang E, Sorolla A, Waryah C, Tie WJ, Cuyàs E, Ratajska M, Kardaś I, Kozlowski P, Johnstone EKM, See HB, Duffy C, Parry J, Lagerborg KA, Czapiewski P, Menendez JA, Gorczyński A, Wasag B, Pfleger KDG, Curtis C, Lee BK, Kim J, Cursons J, Pavlos NJ, Biernat W, Jain M, Woo AJ, Redfern A, Blancafort P. Golden E, et al. Nat Commun. 2021 Mar 26;12(1):1920. doi: 10.1038/s41467-021-22101-7. Nat Commun. 2021. PMID: 33772001 Free PMC article. - Characterization of novel markers of senescence and their prognostic potential in cancer.
Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K, Macip S. Althubiti M, et al. Cell Death Dis. 2014 Nov 20;5(11):e1528. doi: 10.1038/cddis.2014.489. Cell Death Dis. 2014. PMID: 25412306 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous